Michelle Degnin
Papers
1
Total Citations
2
H-Index
1
About
Dr. Michelle Degnin is a dedicated leukemia researcher whose work focuses on rare and aggressive subtypes of acute lymphoblastic leukemia (ALL), particularly those driven by chromosomal translocations. Her most notable contribution is the 2018 study, "Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-HLF rearranged Acute Lymphoblastic Leukemia," which identified a critical vulnerability in this devastating, treatment-resistant leukemia. By demonstrating that TCF3-HLF-rearranged ALL cells are uniquely sensitive to Aurora kinase inhibitors in living models, Dr. Degnin’s work has opened a promising new therapeutic avenue for patients who currently have few options. This research, cited in subsequent studies exploring targeted therapies for high-risk leukemias, underscores her ability to translate molecular insights into actionable treatment strategies. Her findings have helped spotlight the distinct biology of this rare subtype, offering hope for precision medicine approaches where conventional chemotherapy often fails. Dr. Degnin’s contributions exemplify how focused investigation into uncommon diseases can yield breakthroughs with profound clinical implications, inspiring further research into kinase inhibition as a lifeline for patients with the most challenging leukemias.
Research Focus
Key Achievements
Top Papers
- 1